<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655380</url>
  </required_header>
  <id_info>
    <org_study_id>MED-DRU-15-354</org_study_id>
    <nct_id>NCT02655380</nct_id>
  </id_info>
  <brief_title>Remifentanil Requirement for Acceptable Intubating Condition</brief_title>
  <official_title>Remifentanil Requirement for Acceptable Intubating Condition With Two Dose Ketamine Without Neuromuscular Blocking Agent in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine and opioid are known to improve the intubating condition, respectively. Combination
      of ketamine and opioid potentiate analgesic effect and give hemodynamic stability in
      complementary manner. Therefore, the combination use of ketamine and remifentanil could be
      useful for acceptable intubating condition in the general anesthesia without the use of
      neuromuscular blocking agent. Generally, induction dose of ketamine ranges between 1 and 2
      mg. There was no report about the optimal dose of remifentanil with 1 or 2 mg ketamine
      induction dose for intubation without neuromuscular blocking agent. The investigators focus
      on remifentanil dose using Dixon's up and down method.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Actual">April 16, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acceptability of intubation condition</measure>
    <time_frame>during and after intubation, about 2 minute</time_frame>
    <description>For assessment of intubation condition, 5 variables will be individually evaluated though 3 point scale (excellent, good, poor). If all variables are graded as excellent, intubation condition will be excellent. If at least 1 variable is poor, it will be reported as poor. Otherwise, it will be reported as good. Good and excellent will be considered to be acceptable intubating condition. Poor will be reported as unacceptable intubating condition.
Laryngoscope easiness
Vocal cord position
Vocal cord movement
Movement of limb
Coughing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Intubating Condition</condition>
  <arm_group>
    <arm_group_label>ketamine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anesthesia induction with ketamine 1 mg followed by remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anesthesia induction with ketamine 2 mg followed by remifentanil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 1</intervention_name>
    <description>Anesthesia induction is performed with 1 mg ketamine.</description>
    <arm_group_label>ketamine 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 2</intervention_name>
    <description>Anesthesia induction is performed with 2 mg ketamine.</description>
    <arm_group_label>ketamine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.</description>
    <arm_group_label>ketamine 1</arm_group_label>
    <arm_group_label>ketamine 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

          -  Undergoing general anesthesia with endotracheal tube

        Exclusion Criteria:

          -  Anticipated difficult airway

          -  Patient with upper respiratory infection within 14 days

          -  Asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yun jeong chae, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou universitiy school of medicine</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeong-gi Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>yun jeong chae</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

